Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
87 hedge funds and large institutions have $74.3M invested in Adamas Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 12 closing their positions.
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
13% more call options, than puts
Call options by funds: $656K | Put options by funds: $581K
12% more funds holding
Funds holding: 78 → 87 (+9)
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
32% less capital invested
Capital invested by funds: $109M → $74.3M (-$34.9M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.51M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.15M |
| 3 |
Renaissance Technologies
New York
|
+$763K |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$716K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$663K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$13.4M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.15M |
| 3 |
BC
Broadfin Capital
New York
|
-$2.73M |
| 4 |
Millennium Management
New York
|
-$2.02M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$1.33M |
ADMS Hedge Fund Activity: Q3 2019 in Review
87 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2019, worth a combined $74.3M — down 32% from $109M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ADMS positions and 12 closed out — a net gain of 9 holders — while 22 added to existing stakes and 24 trimmed.
The largest buyer was Ameriprise, adding an estimated $1.51M. The largest seller was Armistice Capital, cutting an estimated $13.4M.
- 87 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2019, up from 78 in Q2 2019.
- Funds reported $74.3M of Adamas Pharmaceuticals stock for Q3 2019, down 32% quarter-over-quarter.
- 21 funds opened new Adamas Pharmaceuticals positions in Q3 2019 and 12 closed out, a net change of +9 holders.
- The largest Adamas Pharmaceuticals buyer in Q3 2019 was Ameriprise, an estimated $1.51M added.
- The largest Adamas Pharmaceuticals seller in Q3 2019 was Armistice Capital, an estimated $13.4M sold.
Based on aggregated 13F filings for Q3 2019.